

## Allstar Health Brands Inc

A Nevada Corporation  
80 SW 8th street  
Suite 2000  
Miami, FL 33130

---

Tel: (305) 423 7028  
www.allstarhealthbrands.com  
[danielb@allstarhealthbrands.com](mailto:danielb@allstarhealthbrands.com)

Primary SIC Code: 2836-1;  
Secondary SIC Code: 2834-1.  
CUSIP: 01989F109

### Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines Annual Report For the Period Ending: June 30 2020 (the "Reporting Period")

As of December 31 2019, the number of shares outstanding of our Common Stock was:  
1,314,390 – Corrected for Dec 23 2019 40,000:1 roll back

As of March 31, 2020, the number of shares outstanding of our Common Stock was:  
3,092,074 – Corrected for Dec 23 2019 40,000:1 roll back

As of June 30, 2020, the number of shares outstanding of our Common Stock was:  
3,092,074 – Corrected for Dec 23 2019 40,000:1 roll back

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

#### 1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities and the dates of the name changes.

Predecessor: Axxess Pharma Inc.

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Axxess Pharma, Inc. was incorporated in the state of Delaware on April 7, 1997 as CGI Communications Services Inc. On July 26, 2008, the Company amended its certificate of incorporation to change its name to Axxess Pharma, Inc. On December 6, 2012 the Company reincorporated in Nevada by merging into a newly formed Nevada entity with the name Axxess Pharma, Inc. The Company now operates as Axxess Pharma, Inc. with Axxess Pharma Canada, Inc. and Allstar Health Brands Inc. as its wholly owned subsidiaries.

Axxess Pharma Canada, Inc. was incorporated under the Laws of the Province of Ontario. The Company is engaged in the acquisition of Drug Identification Numbers and the eventual sale of the related products. All Star Health Brands Inc. was incorporated on October 1, 2013 under the Laws of the Province of Ontario. The Company is engaged in the acquisition of Drug Identification Numbers and the eventual sale of the related products.

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐

No: ☒

## 2) Security Information

Trading symbol:	<u>ALST</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>01989F109</u>	
Par or stated value:	<u>\$ .0001</u>	
Total shares authorized:	1,000,000,000	as of date: June 30 2020
Total shares outstanding:	3,092,074	as of date: June 30 2020
Number of shares in the Public Float <sup>2</sup> :	585,609	as of date: June 30 2020
Total number of shareholders of record:	660	as of date: June 30 2020

*Additional class of securities (if any):*

Trading symbol:		
Exact title and class of securities outstanding:	Preferred	
CUSIP:		
Par or stated value:	\$ .0001	
Total shares authorized:	20,000,000	as of date: June 30 2020
Total shares outstanding:	20,000,000	as of date: June 30 2020

### Transfer Agent

Name: Corporate Stock Transfer, Inc  
Phone: (303) 282-4800  
Email: mtampubolon@corporatestock.com

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes: ☒ No: ☐

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On December 23 2019, the Company did a 40,000 for 1 stock roll back.

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Number of shares outstanding as of		Opening Balances	Restated Opening Balances
	Common	63,766	2
1-Jan-18	Preferred	20,000,000	20,000,000

Date of Transaction	Transaction Type	Number of Shares	Number of Shares restated to reflect 40,000:1 rollback Dec 23 2019	Class of Securities	Value of shares issued \$/share	Discounted?	Issued to	Control person if issued to corporate entity	Reason for Issuance	Restricted?
4-Jan-18	new issuance	7,180,854	180	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
8-Jan-18	new issuance	7,029,000	176	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
17-Jan-18	new issuance	8,600,000	215	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
29-Jan-18	new issuance	9,000,000	225	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
30-Jan-18	new issuance	9,700,000	243	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
5-Feb-18	new issuance	2,521,938	63	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
9-Feb-18	new issuance	8,999,999	225	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
26-Feb-18	new issuance	12,700,000	318	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
27-Feb-19	new issuance	12,478,730	312	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted

20-Mar-18	new issuance	7,489,000	187	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
19-Apr-18	new issuance	15,742,237	394	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
19-Apr-18	new issuance	7,880,000	197	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
4-May-18	new issuance	18,102,098	453	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
15-May-18	new issuance	19,910,498	498	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
22-May-18	new issuance	21,899,556	547	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
29-May-18	new issuance	20,224,711	506	common	0.001	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
7-Apr-18	new issuance	26,107,771	653	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
13-Jun-18	new issuance	28,715,936	718	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
18-Jun-18	new issuance	31,584,500	790	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
6-Jul-18	new issuance	34,426,978	861	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
11-Jul-18	new issuance	35,000,000	875	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
25-Jul-18	new issuance	37,500,000	938	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
7-Aug-18	new issuance	45,000,000	1,125	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
26-Aug-18	new issuance	49,750,000	1,244	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
7-Sep-18	new issuance	52,000,000	1,300	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
17-Sep-18	new issuance	59,914,816	1,498	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
27-Sep-18	new issuance	66,067,770	1,652	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
2-Oct-18	new issuance	72,000,000	1,800	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
5-Oct-18	new issuance	73,000,000	1,825	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
18-Oct-18	new issuance	86,000,000	2,150	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
23-Oct-18	new issuance	94,000,000	2,350	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
30-Oct-18	new issuance	102,000,000	2,550	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted

2-Nov-18	new issuance	112,000,000	2,800	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
6-Nov-18	new issuance	94,932,229	2,373	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
12-Nov-18	new issuance	123,000,000	3,075	common	0.000	discounted	LT2 Capital. 411 Dorado Beach East, Dorado PR	Adam Long	debt conversion	restricted
31-Dec-19	new issuance		110,000	common	0.520	discounted	Anthony Italiano, 5160 Explorer Drive, Mississauga, ON L4WT7		working capital	restricted
31-Dec-19	new issuance		100,000	common	0.520	discounted	Carmelo Calabrese, 34 Serene Crt, Whitby, ON L1R 0L6		working capital	restricted
31-Dec-19	new issuance		162,000	common	0.520	discounted	Ed Blasiak, 3 Rowallan Drive, Toronto, ON M1E 2Y5		working capital	restricted
31-Dec-19	new issuance		50,000	common	0.520	discounted	Gus Koutoumonos, 90 North Park Dr, Toronto, ON M6L 1K2		working capital	restricted
31-Dec-19	new issuance		63,313	common	0.500	discounted	Hassan Abugosh, 199 Butterfield Cres, Maple, ON L6A 1L1		debt conversion	restricted
31-Dec-19	new issuance		50,000	common	0.250	discounted	Crone Law Group, Memphis TN 38103	Mark Crone	debt conversion	restricted
31-Dec-19	new issuance		150,000	common	0.750	discounted	Michael Marino, 2390 McDonald Ave, Brooklyn, NY 11223		debt conversion	restricted
31-Dec-19	new issuance		40,000		0.520	discounted	Patrick Pecoraro, 17 Waltham, Dr. Etobicoke, ON M9V 1S6		debt conversion	restricted
31-Dec-19	new issuance		250,000		0.520	discounted	Peter Bagi, 80 SW 8th Street, Suite 2000, Miami, FL 33130		services provided	restricted
31-Dec-19	new issuance		100,000		0.520	discounted	Ramel Shorte, 2622 Swede Road, E-3 East Norriton, PA 19401		working capital	restricted
31-Dec-19	new issuance		100,000		0.520	discounted	Robert Salna, 64 Industrial Rd, Richmond Hill, ON L4C 2Y1		working capital	restricted
31-Dec-19	new issuance		40,000		0.520	discounted	Peter Herezegh, 222 Kendal Ave, Oshawa ON L1G 5B5		working capital	restricted
30-Mar-20	new issuance		136,700		0.960	discounted	GPL Investments, 450 7th Ave, #601, New York, NY	Cosmin Panait	debt conversion	restricted
30-Jan-20	new issuance		1,000,000		1.000	discounted	Blue Ivory Intl, Sterling St, Nassua, Bahamas	Allan Cole	debt conversion	restricted
21-Feb-20	new issuance		150,000		1.000	discounted	Danny Pavlovitch, PO Box 3150 Broadway Nedlands, Western Australia 6009		debt conversion	restricted
2-Feb-20	new issuance		25,000		1.540	discounted	Gus Koutoumonos, 90 North Park Dr, Toronto, ON M6L 1K2		working capital	restricted
2-Feb-20	new issuance		25,000		1.540	discounted	Marco Capista, 255 Firglen Ridge, Woodbridge, ON L4L 1N6		working capital	restricted
21-Feb-20	new issuance		50,000		1.000	discounted	Peter Wanner, Greystone Cres, Georgetown, ON L7G 1G9		services provided	restricted
21-Feb-20	new issuance		390,984		1.000	discounted	Ramos & Ramos, 7 Roughwood Crt, North York	Dominic Alessandro	debt conversion	restricted

Net Change

3,092,074

Shares outstanding on	Closing
-----------------------	---------

June 30 2020	Common	3,092,076
	Preferred	20,000,000

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Date of Note Issuance	Creditor	Outstanding Balance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
25-Feb-16	Bou Trust	14,712	4,212	no set maturity date	40% of VMAP 20 days prior to conversion	John Denoble	working capital
10-Dec-18	Carrollton Ventures LLC	70,146	7,060	no set maturity date	none	Dominc Alessandro	working capital
21-Jul-15	GHS Investments	154,492	54,492	no set maturity date	50% of VMAP 20 days prior to conversion	Mark Grober	expansion, inventory and working capital
4-Jan-16	GHS Investments	75,204	25,204	no set maturity date	50% of VMAP 20 days prior to conversion	Mark Grober	working capital
24-Sep-15	Ramos & Ramos LLC	247,901	70,025	no set maturity date	50% of VMAP 20 days prior to conversion	Dominc Alessandro	expansion, inventory and working capital
20-Oct-15	Ramos & Ramos LLC	755,435	155,435	no set maturity date	\$.01 per share	Dominc Alessandro	expansion, inventory and working capital
1-Jul-16	Ramos & Ramos LLC	145,016	45,016	no set maturity date	60% of VMAP 20 days prior to conversion	Dominc Alessandro	expansion, inventory and working capital
1-Oct-17	Ramos & Ramos LLC	186,188	46,188	no set maturity date	50% of VMAP 20 days prior to conversion	Dominc Alessandro	expansion, inventory and working capital
1-Apr-18	Ramos & Ramos LLC	173,600	33,600	no set maturity date	50% of VMAP 20 days prior to conversion	Dominc Alessandro	expansion, inventory and working capital
17-Oct-18	Ramos & Ramos LLC	163,472	24,347	no set maturity date	50% of VMAP 20 days prior to conversion	Dominc Alessandro	expansion, inventory and working capital
27-May-15	RBB Capital	59,997	34,728	no set maturity date	none	Mark Grober	debt purchased from WHC
5-Feb-15	Redwood Capital	141,746	48,241	no set maturity date	50% of VMAP 20 days prior to conversion	John Denoble	expansion, inventory and working capital
22-Apr-15	Redwood Capital	230,390	80,441	no set maturity date	50% of VMAP 20 days prior to conversion	John Denoble	expansion, inventory and working capital
13-Sep-15	Redwood Capital	92,191	31,191	no set maturity date	50% of VMAP 20 days prior to conversion	John Denoble	working capital
8-Oct-15	Redwood Capital	76,901	24,401	no set maturity date	50% of VMAP 20 days prior to conversion	John Denoble	working capital
13-Nov-15	Redwood Capital	76,321	23,821	no set maturity date	60% of VMAP 20 days prior to conversion	John Denoble	expansion, inventory and working capital
		2,663,712	708,402				

## 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: **Peter Wanner**

Title: **Acting CFO**

Relationship to Issuer: **Contractor**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

Balance sheet;  
Statement of income;  
Statement of cash flows;  
Statement of Changes in Shareholders' Equity  
Financial notes;

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

**AllStar Financial Statements for June 30 2020**

**5) Issuer's Business, Products and Services**

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")
  - The Company has a number of representation agreements, where they are purchasing products from other suppliers and retailing those products through the existing AllStar distribution network. They are selling Natural Health Products
  - The onset of Covid 19, allowed the Company to source and supply various medical elements of the treatment system. The Company sourced Covid 19 testing strips, Personal Protective Equipment and N95 masks. These products represented the majority of the sales for the Company in Q1 and Q2.
  -
- B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference
  - Axxess Health Brands Canada – subsidiary – extension of parent's operations
  - AllStar Health Brands USA Inc – subsidiary – extension of parent's operations

---

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- C. Describe the issuers' principal products or services, and their markets  
Sales and distribution, plus licensing of pharmaceutical OTC and nutraceutical markets

## 6) Issuer's Facilities

The Company has contracted for office space in Florida. No warehouse space is currently under contract.

## 7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Peter Daniel Bagi, MD	CEO	Miami Florida 33130	250,050	Common	5.9%	restricted
Peter Wanner, CGA/CPA	Acting CFO	Georgetown, ON Canada	50,000	Common	1.2%	Restricted
Blue Ivory International Holding, Ltd.		Alan Cole, Director Nassau Bahamas	500	Preferred	100%	
Blue Ivory International Holding, Ltd.		Alan Cole, Director Nassau Bahamas	1,000,251	Common	23.8%	restricted

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None



3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name: Steve Mills- Partner  
Firm: Stephen Mills Attorney  
Address 1: 530 Church Street  
Address 2: Nashville, TN 37203  
Phone: 615 476 1151  
Email: [steve@stevemillslaw.com](mailto:steve@stevemillslaw.com)

### Accountant or Auditor

Name: Steven Rosenberg, CA  
Firm: Rosenberg, Smith & Partners, LLP  
Address 1: 2000 Steeles Avenue West, Suite 200  
Address 2: Concord, ON L4K 3E9  
Phone: 905 695 3565  
Email: [srosenberg@rsp.ca](mailto:srosenberg@rsp.ca)

### Other Service Providers

Name: Peter Wanner  
Firm: Peter Wanner CGA  
Nature of Services: acting CFO  
Address 1: 44 Greystone Crescent,  
Address 2: Georgetown, ON L7G 1G9  
Phone: 416 918 69987  
Email: [petewanner@gmail.com](mailto:petewanner@gmail.com)

**10) Issuer Certification**

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

I, Daniel Bagi certify that:

1. I have reviewed this June 30 2020 filing for Allstar Health Brands Inc. (ALST);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Sept 2 2020

/s/ Daniel Bagi, CEO Signature

*Principal Financial Officer:*

I, Peter Wanner certify that:

1. I have reviewed this annual filing for June 30 2020 of Allstar Health Brands Inc. (ALST);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Sept 2 2020

/s/ Peter Wanner, CFO Signature